References

1. National Cancer Institute. Myeloma Cancer Stat Facts. Available at: www.seer.cancer.gov/statfacts/html/mulmy.html. Accessed on: May 29, 2018.
2. Ailawadhi S, Swaika A, Advani P, et. al. Current State of Patient Awareness and Participation in Care for Multiple Myeloma and the Psychophysical Impact of Treatment: An International Internet-Based Study. Blood. 2014;124:1294.
3. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin in Hematol. 2012, 49 (Suppl 1):S16-S32.
4. American Cancer Society. About Multiple Myeloma. Available at https://www.cancer.org/content/dam/CRC/PDF/Public/8738.00.pdf. Accessed on May 2, 2018.
5. The Multiple Myeloma Research Foundation. Multiple Myeloma Disease Overview. Available at https://www.themmrf.org/assets/mmrf-disease-overview.pdf. Accessed on May 2, 2018.
6. American Cancer Society. Signs and Symptoms of Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/signs-symptoms.html. Accessed on May 2, 2018.
7. American Cancer Society. Risk Factors for Multiple Myeloma. Available at: https://www.cancer.org/cancer/multiple-myeloma/causes-risks-prevention/risk-factors.html. Accessed on May 2, 2018.
8. National Cancer Institute. Understanding Cancer Prognosis. Available at https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis#cure-remission-difference. Accessed on June 1, 2018.
9. Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2015; 30(5):1005-17.
10. Durie BGM. Multiple Myeloma - Concise Review of the Disease and Treatment Options, 2017 Edition. International Myeloma Foundation. Accessed 06/13/2018.
11. American Cancer Society. Drug Therapy for Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html. Accessed on May 2, 2018.
12. The Multiple Myeloma Research Foundation. Standard Treatments. Available at https://themmrf.org/multiple-myeloma/treatment-options/standard-treatments/. Accessed on May 2, 2018.
13. Quach H, Ritchie D, Stewart SK, et. Al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 24(1): 22–32.
14. Terpos E, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347-57.
15. NIH. Iron-Deficiency Anemia: Signs, Symptoms, and Complications. Available at https://www.nhlbi.nih.gov/health-topics/iron-deficiency-anemia. Accessed on May 2, 2018.
16. Bhowmik D, et al. Prevalence Of Renal Impairment In Patients With Multiple Myeloma: Analysis Of Real-World Database. Journal of the International Society for Pharmacoeconomic and Outcomes Research. 2016;9(3):A141.
17. Blimark C, Holmberg E, Mellqvist UH, et. al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100 (1) 107-113.